Global Dermatology Market 2013-2023
The Global Dermatology Market 2013-2023 covers the Pharmaceutical, Commercial, & Strategic Developments in Global Dermatology across the next decade. The report analyses how this important pharma sector will develop over the next ten years.
The report quantifies the market in terms of global size and breaks the market down into key leading countries with forecasts and analysis provided for each of these markets from 2013-2023. The report also examines the major drivers and restraints influencing the market over the next decade and explains the pharmaceutical developments within the market, analysing which companies will drive R&D in the Dermatology sectors.
GMR Data’s The Global Dermatology Market 2013-2023 report details the prospects for this dynamic pharmaceutical sector with detailed forecasts from 2013-2023. The report will be valuable to those already involved in the dermatology market or to those wishing to enter this important market in the future.
The Global Dermatology Market 2013-2023 report includes 170 pages, which include over 160 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers profiles of the 13 leading companies in the dermatology market, alongside 3 interviews with:
The report quantifies the market in terms of global size and breaks the market down into key leading countries with forecasts and analysis provided for each of these markets from 2013-2023. The report also examines the major drivers and restraints influencing the market over the next decade and explains the pharmaceutical developments within the market, analysing which companies will drive R&D in the Dermatology sectors.
GMR Data’s The Global Dermatology Market 2013-2023 report details the prospects for this dynamic pharmaceutical sector with detailed forecasts from 2013-2023. The report will be valuable to those already involved in the dermatology market or to those wishing to enter this important market in the future.
The Global Dermatology Market 2013-2023 report includes 170 pages, which include over 160 tables, charts and graphs quantifying and forecasting the market in detail. In addition, the report offers profiles of the 13 leading companies in the dermatology market, alongside 3 interviews with:
- Cutting edge R&D company; KLOX Technologies Inc of Canada
- Highly experienced dermatology doctor; Dr Keong of Garden Clinic Haroo, Tokyo
- And the world’s largest rosacea forum; the Global Rosacea Forum.
CHAPTER 1 EXECUTIVE SUMMARY
1.1. Dermatological Drugs Market Review
1.2. Chapter Breakdown
1.3. Research and Analysis Methods
CHAPTER 2 INTRODUCTION TO DERMATOLOGICAL DISEASES AND TREATMENTS
2.1 Structure and Function of Human Skin
2.2 Dermatological Conditions & Skin disorders
2.2.1 Acne (Acne Vulgaris)
2.2.1.1 Types & Symptoms of Acne
2.2.1.2 Current Treatments for Acne
2.2.2 Dermatitis
2.2.2.1 Types & Symptoms of Dermatitis
2.2.2.2 Current Treatments for Dermatitis
2.2.3 Psoriasis
2.2.3.1 Types & Symptoms of Psoriasis
2.2.3.2 Current Treatments for Psoriasis
2.2.4 Skin Cancer
2.2.4.1 Types & Symptoms of Skin Cancer
2.2.4.2 Current Treatments for Skin Cancer
2.2.5 Skin Infections
2.2.5.1 Types & Symptoms of Skin Infections
2.2.5.2 Current Treatments for Skin Infections
2.2.6 Rosacea
2.2.6.1 Types & Symptoms of Rosacea
2.2.6.2 Current Treatments for Rosacea
2.2.7 Alopecia
2.2.7.1 Types & Symptoms of Alopecia
2.2.7.2 Current Treatments for Alopecia
CHAPTER 3 CURRENT TRENDS & DEVELOPMENTS IN THE DERMATOLOGY MARKET 2013-2023
3.1 Current Trends & Development
3.2 Major Players – Landscape
CHAPTER 4 DERMATOLOGICAL DRUGS MARKET & FORECAST
4.1 Global Acne Market – 2013 -2023
4.1.1 Major Trends & Issues
4.1.2 Market Size & Forecast
4.1.3 Major Drugs & Forecast
4.1.4 New Developments
4.1.5 Future Pipeline Analysis
4.1.6 The World Acne Drug Market – Summary
4.2 Global Psoriasis Market – 2013 -2023
4.2.1 Major Trends & Issues
4.2.2 Market Size & Forecast
4.2.3 Biologics
4.2.4 Future Pipeline Analysis
4.2.5 The World Psoriasis Drug Market – Summary
4.3 Global Atopic Dermatitis Market – 2013 -202
4.3.1 Major Trends & Issues
4.3.2 Market Size & Forecast
4.3.3 Biologics
4.3.4 Future Pipeline Analysis
4.3.5 The World Atopic Dermatitis Drug Market – Summary
4.4 Global Skin Cancer Market – 2013 -2023
4.4.1 Major Trends & Issues
4.4.2 Market Size & Forecast
4.4.3 Major Drugs & Forecast
4.4.4 New Product Pipeline
4.4.5 The World Skin Cancer Drug Market – Summary
4.5 Global Skin Infections Market – 2013 -2023
4.5.1 Major Trends & Issues
4.5.2 Market Size & Forecast
4.5.3 Major Drugs & Forecast
4.5.4 New Product Pipeline
4.6 Global Rosacea Market – 2013 -2023
4.6.1 Major Trends & Issues
4.6.2 Market Size & Forecast
4.6.3 Major Drugs
4.6.4 New Product Pipeline
4.7 Global Alopecia Market – 2013 -2023
4.7.1 Major Trends & Issues
4.7.2 Market Size & Forecast
4.7.3 Biologics
4.7.4 Future Drug Pipeline Analysis
4.7.5 The World Alopecia Drug Market – Summary
CHAPTER 5 LEADING COMPANIES IN THE GLOBAL DERMATOLOGICAL MARKET
5.1 Allergan, Inc
5.2 Bayer AG
5.3 Galderma
5.4 Valeant Pharmaceuticals International, Inc
5.5 Stiefel Laboratories, Inc
5.6 Novartis, Inc
5.7 Almirall, S.A
5.8 Derma Sciences
5.9 Hill Dermaceuticals, Inc
5.10 Biofrontera AG
5.11 Merck & Co. Inc
5.12 Merz Pharma Group
5.13 Laboratories Pierre Fabre
CHAPTER 6 KEY NATIONAL MARKETS IN THE GLOBAL DERMATOLOGY SECTOR 2013-2023
6 Global Outlook 2013-2023
6.2 The US Dermatology Market 2013-2023
6.3 The UK Dermatology Market 2013-2023
6.4 The French Dermatology Market 2013-2023
6.5 The German Dermatology Market 2013-2023
6.6 The Spanish Dermatology Market 2013-2023
6.7 The Italian Dermatology Market 2013-2023
6.8 The Japanese Dermatology Market 2013-2023
6.9 The Rest of the World Dermatology Market 2013-2023
CHAPTER 7 EXPERT OPINION
7.1 Klox Technologies Inc.
7.2 Global Rosacea Forum
7.3 Dr. Chin-Huai Keong
1.1. Dermatological Drugs Market Review
1.2. Chapter Breakdown
1.3. Research and Analysis Methods
CHAPTER 2 INTRODUCTION TO DERMATOLOGICAL DISEASES AND TREATMENTS
2.1 Structure and Function of Human Skin
2.2 Dermatological Conditions & Skin disorders
2.2.1 Acne (Acne Vulgaris)
2.2.1.1 Types & Symptoms of Acne
2.2.1.2 Current Treatments for Acne
2.2.2 Dermatitis
2.2.2.1 Types & Symptoms of Dermatitis
2.2.2.2 Current Treatments for Dermatitis
2.2.3 Psoriasis
2.2.3.1 Types & Symptoms of Psoriasis
2.2.3.2 Current Treatments for Psoriasis
2.2.4 Skin Cancer
2.2.4.1 Types & Symptoms of Skin Cancer
2.2.4.2 Current Treatments for Skin Cancer
2.2.5 Skin Infections
2.2.5.1 Types & Symptoms of Skin Infections
2.2.5.2 Current Treatments for Skin Infections
2.2.6 Rosacea
2.2.6.1 Types & Symptoms of Rosacea
2.2.6.2 Current Treatments for Rosacea
2.2.7 Alopecia
2.2.7.1 Types & Symptoms of Alopecia
2.2.7.2 Current Treatments for Alopecia
CHAPTER 3 CURRENT TRENDS & DEVELOPMENTS IN THE DERMATOLOGY MARKET 2013-2023
3.1 Current Trends & Development
3.2 Major Players – Landscape
CHAPTER 4 DERMATOLOGICAL DRUGS MARKET & FORECAST
4.1 Global Acne Market – 2013 -2023
4.1.1 Major Trends & Issues
4.1.2 Market Size & Forecast
4.1.3 Major Drugs & Forecast
4.1.4 New Developments
4.1.5 Future Pipeline Analysis
4.1.6 The World Acne Drug Market – Summary
4.2 Global Psoriasis Market – 2013 -2023
4.2.1 Major Trends & Issues
4.2.2 Market Size & Forecast
4.2.3 Biologics
4.2.4 Future Pipeline Analysis
4.2.5 The World Psoriasis Drug Market – Summary
4.3 Global Atopic Dermatitis Market – 2013 -202
4.3.1 Major Trends & Issues
4.3.2 Market Size & Forecast
4.3.3 Biologics
4.3.4 Future Pipeline Analysis
4.3.5 The World Atopic Dermatitis Drug Market – Summary
4.4 Global Skin Cancer Market – 2013 -2023
4.4.1 Major Trends & Issues
4.4.2 Market Size & Forecast
4.4.3 Major Drugs & Forecast
4.4.4 New Product Pipeline
4.4.5 The World Skin Cancer Drug Market – Summary
4.5 Global Skin Infections Market – 2013 -2023
4.5.1 Major Trends & Issues
4.5.2 Market Size & Forecast
4.5.3 Major Drugs & Forecast
4.5.4 New Product Pipeline
4.6 Global Rosacea Market – 2013 -2023
4.6.1 Major Trends & Issues
4.6.2 Market Size & Forecast
4.6.3 Major Drugs
4.6.4 New Product Pipeline
4.7 Global Alopecia Market – 2013 -2023
4.7.1 Major Trends & Issues
4.7.2 Market Size & Forecast
4.7.3 Biologics
4.7.4 Future Drug Pipeline Analysis
4.7.5 The World Alopecia Drug Market – Summary
CHAPTER 5 LEADING COMPANIES IN THE GLOBAL DERMATOLOGICAL MARKET
5.1 Allergan, Inc
5.2 Bayer AG
5.3 Galderma
5.4 Valeant Pharmaceuticals International, Inc
5.5 Stiefel Laboratories, Inc
5.6 Novartis, Inc
5.7 Almirall, S.A
5.8 Derma Sciences
5.9 Hill Dermaceuticals, Inc
5.10 Biofrontera AG
5.11 Merck & Co. Inc
5.12 Merz Pharma Group
5.13 Laboratories Pierre Fabre
CHAPTER 6 KEY NATIONAL MARKETS IN THE GLOBAL DERMATOLOGY SECTOR 2013-2023
6 Global Outlook 2013-2023
6.2 The US Dermatology Market 2013-2023
6.3 The UK Dermatology Market 2013-2023
6.4 The French Dermatology Market 2013-2023
6.5 The German Dermatology Market 2013-2023
6.6 The Spanish Dermatology Market 2013-2023
6.7 The Italian Dermatology Market 2013-2023
6.8 The Japanese Dermatology Market 2013-2023
6.9 The Rest of the World Dermatology Market 2013-2023
CHAPTER 7 EXPERT OPINION
7.1 Klox Technologies Inc.
7.2 Global Rosacea Forum
7.3 Dr. Chin-Huai Keong
LIST OF TABLES
Table 2.2.1 Acne Type & Symptoms
Table 2.2.2 Dermatitis Types & Symptoms
Table 2.2.2.1.a Major drugs for Dermatitis in the Market
Table 2.2.2.2.a Dermatitis Drug Pipeline
Table 2.2.3.1 Psoriasis Types & Symptoms
Table2.2.3.1.a Prevalence of Psoriasis in Selected Countries Worldwide 2013
Table 2.2.3.3.a Psoriasis Phase 3 Drugs Pipeline
Table 2.2.3.3.b Psoriasis Phase 2 Drugs Pipeline
Table 2.2.4 Skin Cancer Types & Symptoms
Table 2.2.4.1 Skin Cancer Types & Symptoms
Table 2.2.4.3 Skin Cancer Types & Symptoms
Table 2.2.5.a Bacterial Infection Types & Symptoms
Table 2.2.5.b Viral Infection Types & Symptoms
Table 2.2.5.c Fungal Infection Types & Symptoms
Table 2.2.5.d Parasitic Infection Types & Symptoms
Table 2.2.5.1 Major Drugs for Skin Infection in the Market
Table 2.2.5.3 Skin Infection Drug Pipeline
Table 2.2.6.1 Skin Infection Drug Pipeline
Table 2.2.7: Alopecia Types & Symptoms
Table 2.2.7.1 Major Drugs for Alopecia
Table 2.2.7.2 Alopecia Drugs Pipeline
Table 3.2.1 Merger & Acquisitions
Table 4.a Market Size & Forecast – Global Dermatological Drugs
Table 4.b Global Dermatological Drug Market Forecast ($/bn, P/A, CAGR)
Table 4.1.2.a Market Size & Forecast – Acne Market ($/m, P/A, CAGR)
Table 4.1.2.b Acne Drugs Market Share – By Revenue ($/bn, P/A, CAGR)
Table 4.1.3.1 Market Forecast for Solodyn ($/m, P/A, CAGR)
Table 4.1.3.2 Market Forecast for Isotretinoin ($/m, P/A, CAGR)
Table 4.1.3.3 Market Forecast for Doryx ($/m, P/A, CAGR)
Table 4.1.3.4 Market Forecast for Diane ($/m, P/A, CAGR)
Table 4.1.3.5 Market Forecast for Ziana ($/m, P/A, CAGR)
Table 4.1.4.1 Acne Drugs R&D Pipeline 2013
Table 4.2.2.a Market Size & Forecast – Psoriasis Market ($/m, P/A, CAGR)
Table 4.2.3.1 Total Enbrel Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.2 Enbrel Forecasting for Psoriatic Treatment ($/m, P/A, CAGR)
Table 4.2.3.3 Total Humira Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.4 Humira Forecasting for Psoriatic Treatment ($/m, P/A, CAGR)
Table 4.2.3.5 Total Remicade Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.5 Total Stelara Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.6 Total Simponi Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.3.2.1 Market Size & Forecast for Atopic Dermatitis ($/m, P/A, CAGR)
Table 4.3.3.1 Revenue of Protopic ($/m, P/A, CAGR)
Table 4.3.3.2 Market Size & Forecast for Protopic ($/m, P/A, CAGR)
Table 4.4.2.4 Revenue for Elidel ($/m, P/A, CAGR)
Table 4.3.3.3 Market Size & Forecast for Elidel ($/m, P/A, CAGR)
Table 4.3.3.4 Revenue for Clobex ($/m, P/A, CAGR)
Table 4.3.3.5 Market Size & Forecast for Clobex ($/m, P/A, CAGR)
Table 4.3.3.6 Revenue for Elocon ($/m, P/A, CAGR)
Table 4.3.3.7 Market Size & Forecast for Elocon ($/m, P/A, CAGR)
Table 4.4.2.1 Market Size & Forecast for Melanoma Skin Cancer ($/bn, P/A, CAGR)
Table 4.4.2.2 Revenue of Yervoy ($/m, P/A, CAGR)
Table 4.4.2.3 Market Size & Forecast for Yervoy ($/m, P/A, CAGR)
Table 4.4.2.4 Revenue of Zelboraf ($/m, P/A, CAGR)
Table 4.4.2.5 Market Size & Forecast for Zelboraf ($/m, P/A, CAGR)
Table 4.5.2.1 Market Size & Forecast for Skin and Skin Structure Infections ($/bn, P/A, CAGR)
Table 4.5.2.2 Market Size & Forecast for Herpes ($/bn, P/A, CAGR)
Table 4.5.3.1 Revenue of Zyvox ($/m, P/A, CAGR)
Table 4.5.3.2 Market Size & Forecast for Zyvox ($/m, P/A, CAGR)
Table 4.5.3.3 Revenue for Cubicin ($/m, P/A, CAGR)
Table 4.5.3.4 Market Size & Forecast for Cubicin ($/m, P/A, CAGR)
Table 4.5.3.5 Revenue for Zovirax ($/m, P/A, CAGR)
Table 4.5.3.6 Market Size & Forecast for Zovirax ($/m, P/A, CAGR)
Table 4.5.3.7 Revenue for Valtrex ($/m, P/A, CAGR)
Table 4.5.3.8 Market Size & Forecast for Valtrex ($/m, P/A, CAGR)
Table 4.5.3.9 Revenue for Zostavax ($/m, P/A, CAGR)
Table 4.5.3.10 Market Size & Forecast for Zostavax ($/m, P/A, CAGR)
Table 4.6.2.1 Market Size & Forecast – Rosacea Market ($/bn, P/A, CAGR)
Table 4.6.3.1 Major Drugs – Rosacea Market ($/bn, P/A, CAGR)
Table 4.6.3.2 Oracea Forecasting for Rosacea Treatment ($/m, P/A, CAGR)
Table 4.6.4.1 New Product Pipeline for Rosacea Treatment
Table 4.7.2.1 Market Size & Forecast for Alopecia ($/bn P/A, CAGR)
Table 4.7.3.1 Revenue of Propecia ($/m, P/A, CAGR)
Table 4.7.3.2 Market Size & Forecast for Propecia ($/m, P/A, CAGR)
Table 4.7.3.3 Market Size & Forecast for Rogaine ($/m, P/A, CAGR)
Table 5.1.1 Allergan Products Overview
Table 5.1.2 Allergan R&D Pipeline in the Dermatology Segment – 2012
Table 5.2.1 Bayer’s Key Dermatology Products 2013
Table 5.2.2 Bayer’s R&D Pipeline - 2013
Table 5.3.1 Galderma Key Dermatology Products 2013
Table 5.4.1 Valeant Key Dermatology Products 2013
Table 5.4.2 Valeant’s R&D Pipeline
Table 5.5.1 Stiefel’s Products Overview 2013
Table 5.5.2 Stiefel R&D Pipeline in the Dermatology Segment - 2013
Table 5.6.1 Novartis (Fougera) Products Overview
Table 5.6.2 Novartis R&D Pipeline in the Dermatology Segment - 2013
Table 5.7.1 Almirall Products Overview
Table 5.7.2 Almirall R&D Pipeline in the Dermatology Segment - 2013
Table 5.9.1 Hill Products Overview
Table 5.10.1 Biofrontera Product Overview
Table 5.10.2 Biofrontera Drug Pipeline
Table 5.11.1 Merck & Co, Inc Product Overview
Table 5.11.2 Merck & Co, Inc Drug Pipeline
Table 5.12.1 Merz Product Overview
Table 5.13.1 Pierre Fabre Product Overview
Table 6.0.1 The Global Dermatology Market Forecast 2011 -2023, by Country ($/bn, P/A, CAGR)
Table 6.0.2 Key Countries CAGR 2013-2023 (%)
Table 6.0.3 Estimated Dermatological Market Share for Selected Countries 2013, 2018 and 2023 (%)
Table 6.0.7 Total Healthcare Expenditure per Capita 2011, Sample countries ($/p/a)
Table 6.1.1 The US Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.2.1 The UK Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.3.1 The French Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.4.1 The German Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.5.1 The Spanish Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.6.1 The Italian Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.7.1 The Japanese Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.8.1 The ROW Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.8.3 BRIC Population, GDP 2000 & 2010, CAGR & GDP per Capita 2000 & 2010 ($)
Table 6.8.4 Galderma & Novartis Global HQ, R&D and Manufacturing Sites
Table 2.2.1 Acne Type & Symptoms
Table 2.2.2 Dermatitis Types & Symptoms
Table 2.2.2.1.a Major drugs for Dermatitis in the Market
Table 2.2.2.2.a Dermatitis Drug Pipeline
Table 2.2.3.1 Psoriasis Types & Symptoms
Table2.2.3.1.a Prevalence of Psoriasis in Selected Countries Worldwide 2013
Table 2.2.3.3.a Psoriasis Phase 3 Drugs Pipeline
Table 2.2.3.3.b Psoriasis Phase 2 Drugs Pipeline
Table 2.2.4 Skin Cancer Types & Symptoms
Table 2.2.4.1 Skin Cancer Types & Symptoms
Table 2.2.4.3 Skin Cancer Types & Symptoms
Table 2.2.5.a Bacterial Infection Types & Symptoms
Table 2.2.5.b Viral Infection Types & Symptoms
Table 2.2.5.c Fungal Infection Types & Symptoms
Table 2.2.5.d Parasitic Infection Types & Symptoms
Table 2.2.5.1 Major Drugs for Skin Infection in the Market
Table 2.2.5.3 Skin Infection Drug Pipeline
Table 2.2.6.1 Skin Infection Drug Pipeline
Table 2.2.7: Alopecia Types & Symptoms
Table 2.2.7.1 Major Drugs for Alopecia
Table 2.2.7.2 Alopecia Drugs Pipeline
Table 3.2.1 Merger & Acquisitions
Table 4.a Market Size & Forecast – Global Dermatological Drugs
Table 4.b Global Dermatological Drug Market Forecast ($/bn, P/A, CAGR)
Table 4.1.2.a Market Size & Forecast – Acne Market ($/m, P/A, CAGR)
Table 4.1.2.b Acne Drugs Market Share – By Revenue ($/bn, P/A, CAGR)
Table 4.1.3.1 Market Forecast for Solodyn ($/m, P/A, CAGR)
Table 4.1.3.2 Market Forecast for Isotretinoin ($/m, P/A, CAGR)
Table 4.1.3.3 Market Forecast for Doryx ($/m, P/A, CAGR)
Table 4.1.3.4 Market Forecast for Diane ($/m, P/A, CAGR)
Table 4.1.3.5 Market Forecast for Ziana ($/m, P/A, CAGR)
Table 4.1.4.1 Acne Drugs R&D Pipeline 2013
Table 4.2.2.a Market Size & Forecast – Psoriasis Market ($/m, P/A, CAGR)
Table 4.2.3.1 Total Enbrel Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.2 Enbrel Forecasting for Psoriatic Treatment ($/m, P/A, CAGR)
Table 4.2.3.3 Total Humira Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.4 Humira Forecasting for Psoriatic Treatment ($/m, P/A, CAGR)
Table 4.2.3.5 Total Remicade Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.5 Total Stelara Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.2.3.6 Total Simponi Sales 2010, 2011 & 2012 ($/m, CAGR)
Table 4.3.2.1 Market Size & Forecast for Atopic Dermatitis ($/m, P/A, CAGR)
Table 4.3.3.1 Revenue of Protopic ($/m, P/A, CAGR)
Table 4.3.3.2 Market Size & Forecast for Protopic ($/m, P/A, CAGR)
Table 4.4.2.4 Revenue for Elidel ($/m, P/A, CAGR)
Table 4.3.3.3 Market Size & Forecast for Elidel ($/m, P/A, CAGR)
Table 4.3.3.4 Revenue for Clobex ($/m, P/A, CAGR)
Table 4.3.3.5 Market Size & Forecast for Clobex ($/m, P/A, CAGR)
Table 4.3.3.6 Revenue for Elocon ($/m, P/A, CAGR)
Table 4.3.3.7 Market Size & Forecast for Elocon ($/m, P/A, CAGR)
Table 4.4.2.1 Market Size & Forecast for Melanoma Skin Cancer ($/bn, P/A, CAGR)
Table 4.4.2.2 Revenue of Yervoy ($/m, P/A, CAGR)
Table 4.4.2.3 Market Size & Forecast for Yervoy ($/m, P/A, CAGR)
Table 4.4.2.4 Revenue of Zelboraf ($/m, P/A, CAGR)
Table 4.4.2.5 Market Size & Forecast for Zelboraf ($/m, P/A, CAGR)
Table 4.5.2.1 Market Size & Forecast for Skin and Skin Structure Infections ($/bn, P/A, CAGR)
Table 4.5.2.2 Market Size & Forecast for Herpes ($/bn, P/A, CAGR)
Table 4.5.3.1 Revenue of Zyvox ($/m, P/A, CAGR)
Table 4.5.3.2 Market Size & Forecast for Zyvox ($/m, P/A, CAGR)
Table 4.5.3.3 Revenue for Cubicin ($/m, P/A, CAGR)
Table 4.5.3.4 Market Size & Forecast for Cubicin ($/m, P/A, CAGR)
Table 4.5.3.5 Revenue for Zovirax ($/m, P/A, CAGR)
Table 4.5.3.6 Market Size & Forecast for Zovirax ($/m, P/A, CAGR)
Table 4.5.3.7 Revenue for Valtrex ($/m, P/A, CAGR)
Table 4.5.3.8 Market Size & Forecast for Valtrex ($/m, P/A, CAGR)
Table 4.5.3.9 Revenue for Zostavax ($/m, P/A, CAGR)
Table 4.5.3.10 Market Size & Forecast for Zostavax ($/m, P/A, CAGR)
Table 4.6.2.1 Market Size & Forecast – Rosacea Market ($/bn, P/A, CAGR)
Table 4.6.3.1 Major Drugs – Rosacea Market ($/bn, P/A, CAGR)
Table 4.6.3.2 Oracea Forecasting for Rosacea Treatment ($/m, P/A, CAGR)
Table 4.6.4.1 New Product Pipeline for Rosacea Treatment
Table 4.7.2.1 Market Size & Forecast for Alopecia ($/bn P/A, CAGR)
Table 4.7.3.1 Revenue of Propecia ($/m, P/A, CAGR)
Table 4.7.3.2 Market Size & Forecast for Propecia ($/m, P/A, CAGR)
Table 4.7.3.3 Market Size & Forecast for Rogaine ($/m, P/A, CAGR)
Table 5.1.1 Allergan Products Overview
Table 5.1.2 Allergan R&D Pipeline in the Dermatology Segment – 2012
Table 5.2.1 Bayer’s Key Dermatology Products 2013
Table 5.2.2 Bayer’s R&D Pipeline - 2013
Table 5.3.1 Galderma Key Dermatology Products 2013
Table 5.4.1 Valeant Key Dermatology Products 2013
Table 5.4.2 Valeant’s R&D Pipeline
Table 5.5.1 Stiefel’s Products Overview 2013
Table 5.5.2 Stiefel R&D Pipeline in the Dermatology Segment - 2013
Table 5.6.1 Novartis (Fougera) Products Overview
Table 5.6.2 Novartis R&D Pipeline in the Dermatology Segment - 2013
Table 5.7.1 Almirall Products Overview
Table 5.7.2 Almirall R&D Pipeline in the Dermatology Segment - 2013
Table 5.9.1 Hill Products Overview
Table 5.10.1 Biofrontera Product Overview
Table 5.10.2 Biofrontera Drug Pipeline
Table 5.11.1 Merck & Co, Inc Product Overview
Table 5.11.2 Merck & Co, Inc Drug Pipeline
Table 5.12.1 Merz Product Overview
Table 5.13.1 Pierre Fabre Product Overview
Table 6.0.1 The Global Dermatology Market Forecast 2011 -2023, by Country ($/bn, P/A, CAGR)
Table 6.0.2 Key Countries CAGR 2013-2023 (%)
Table 6.0.3 Estimated Dermatological Market Share for Selected Countries 2013, 2018 and 2023 (%)
Table 6.0.7 Total Healthcare Expenditure per Capita 2011, Sample countries ($/p/a)
Table 6.1.1 The US Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.2.1 The UK Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.3.1 The French Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.4.1 The German Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.5.1 The Spanish Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.6.1 The Italian Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.7.1 The Japanese Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.8.1 The ROW Dermatology Market Forecast 2011-2023 ($/bn, P/A, CAGR, %)
Table 6.8.3 BRIC Population, GDP 2000 & 2010, CAGR & GDP per Capita 2000 & 2010 ($)
Table 6.8.4 Galderma & Novartis Global HQ, R&D and Manufacturing Sites
LIST OF FIGURES
Figure 2.2.3.1 Breakdown by Type , Psoriasis
Figure 2.2.4.1 Global Market Size as per Skin Cancer Type – Incidences
Figure 4.a Global Dermatological Drug Market Growth
Figure 4.b Global Dermatological Drug Market Share – By Revenue
Figure 4.1.2.a Acne Market Growth
Figure 4.1.2.b. Acne Drugs Market Share – By Revenue
Figure 4.1.3.1 Solodyn Market Growth
Figure 4.1.3.2 Isotretinoin Market Growth
Figure 4.1.3.3 Doryx Market Growth
Figure 4.1.3.4 Diane Market Growth
Figure 4.1.3.5 Ziana Market Growth
Figure 4.2.2.a Psoriasis Market Growth
Figure 4.2.2.b Overall Psoriatic therapeutic market - Growth from 2012 to 2013
Figure 4.2.3.1 Enbrel Market Growth
Figure 4.2.3.2 Humira Market Growth
Figure 4.3.2.1 Atopic Dermatitis Market Growth
Figure 4.3.3.1 Protopic Market Value
Figure 4.3.3.2 Elidel Market Growth
Figure 4.3.3.3 Clobex Market Growth
Figure 4.3.3.4 Elocon Market Growth
Figure 4.4.2.1 Melanoma Skin Cancer Market Growth
Figure 4.4.2.2 Yervoy Market Growth
Figure 4.4.2.3 Zelboraf Market Growth
Figure 4.5.2.1 Skin & Skin Structure Infections Market
Figure 4.5.2.2 Herpes Market
Figure 4.5.3.1 Zyvox Market Growth
Figure 4.5.3.2 Cubicin Market Growth
Figure 4.5.3.3 Zovirax Market Growth
Figure 4.5.3.4 Valtrex Market Growth
Figure 4.5.3.5 Zostavax Market Growth
Figure 4.6.2.a Zostavax Market Growth
Figure 4.6.3.1 Rosacea Market Growth
Figure 4.6.3.2 Oracea Market Growth
Figure 4.7.2.1 Alopecia Market Growth
Figure 4.7.3.1 Propecia Market Growth
Figure 4.7.3.2 Rogaine Market Growth
Figure 6.0.4 Global Market Share for Selected Countries 2013
Figure 6.0.5 Global Market Share for Selected Countries 2018
Figure 6.o.6 Global Market Share for Selected Countries 2023
Figure 6.1.2 The US Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.2.2 The UK Dermatology Market Forecast Figure 2011-2023 ($/bn)
Figure 6.3.2 The French Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.4.2 The German Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.5.2 The Spanish Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.6.2 The Italian Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.7.2 The Japanese Dermatology Market Forecast 2011-2023 ($/bn)
Table 6.8.2 The ROW Dermatology Market Forecast 2011-2023 ($/bn)
COMPANIES MENTIONED IN THIS REPORT
AAIPharma Services
Abbott
AbbVie Inc
Actavis
Actelion
Aderans Research Institute
Alcon
Allergan, Inc
Almirall, S.A
Amgen
Anacor Pharmaceutical
Anacor Pharmaceuticals
AndroScience Corporation
ApoPharma
Array Biopharma
Ascent Pharmahealth
Aspen Pharmacare
Astellas Pharma
AstraZeneca
AstraZeneca
BASF Pharma
Basilea Pharmaceutica Ltd
Bayer AG
BioForm Medical, Inc
Biofrontera AG
Biofrontera Bioscience GmbH
Biofrontera Pharma GmbH
BioMAS Ltd.
Biotest
Biovail Corporation
Bipharma
BMS
Bristol-Myers Squibb
Can-Fite BioPharma
Celegene Corporation
Cobrek Pharmaceuticals
CollaGenex Pharmaceuticals
Coria Laboratories, Ltd
Cosmo Pharama
Cosmo Pharmaceuticals
Creabilis Therapeutics
Cubist
Cutanea Life sciences
Derma Sciences, Inc
Dermik
Dow Pharmaceutical
DUSA Pharmaceuticals
Eisai Ltd.
Eli Lily
Elorac
EMO-FARM Ltd
Excaliard Pharmaceuticals
Forest Laboratories
Forward-Pharma GmbH
Fougera Pharmaceuticals
Furiex Pharmaceuticals
Galderma
Genzyme
GlaxoSmithKline
Glenmark
Graceway Pharmaceuticals
Helix Biomedix
Heritage Pharmaceuticals
Hill Dermaceuticals, Inc
Hygeia Therapeutics
Hygeia Therapeutics
Immunotech
Impax
Incyte
Intendis
Intendis GmbH
Ipsen
Isotecknika
Italfarmaco
Janssen Biotech
Johnson & Johnson
Kuhnil Pharmaceutical
Laboratoires Roche
Leo Pharma
L'Oréal
Lundbeck
Maruho
Maruho Co. Ltd.
McNeil-PPC
Meda AB
Medarex
MedEfficiency
Medicis
Merck & Co. Inc
Merz Pharma Group
Morria
Mylan
Mylan Inc
Nabriva Therapeutics
Nektar
Nestlé
Novartis, Inc
Obagi
Ortho Dermatologics
Ortho Dermatologics
Paddock
Paddock Laboratories
Paratek Pharmaceuticals
Pelpharma
Perigo
Perrigo
Pfizer
PHA Farmed s.p.
Pharma.MT Ltd
Pharmacenter
Pierre Fabre
PreCision Dermatology
Provectus Pharmaceuticals
Q-Med
Ranbaxy
Rib-X Pharmaceuticals
R-Tech Ueno Ltd
Sandoz
Sanofi
Sanofi Aventis
Schering AG
Schering-Plough
SkinMedica, Inc
Spirig Pharma
Stiefel Laboratories, Inc
Sun Pharmaceutical
Takeda
Targanta Therapeutics
TaroPharma
Tetraphase Pharmaceuticals
The Medicine Company
Theravance
Triax Pharmaceuticals
Trius Therapeutics
Trius Therapeutics, Inc
UCB Inc
University Hospital of Bordeaux
Upjohn
Valeant Pharmaceuticals International, Inc
VBL Therapeutics
Vicept Therapeutics
Warner Chilcott
Watson Pharma Inc
Welichem Biotech
Welichem Biotech Inc.
Wellspring Pharmaceuticals
York Pharma
Figure 2.2.3.1 Breakdown by Type , Psoriasis
Figure 2.2.4.1 Global Market Size as per Skin Cancer Type – Incidences
Figure 4.a Global Dermatological Drug Market Growth
Figure 4.b Global Dermatological Drug Market Share – By Revenue
Figure 4.1.2.a Acne Market Growth
Figure 4.1.2.b. Acne Drugs Market Share – By Revenue
Figure 4.1.3.1 Solodyn Market Growth
Figure 4.1.3.2 Isotretinoin Market Growth
Figure 4.1.3.3 Doryx Market Growth
Figure 4.1.3.4 Diane Market Growth
Figure 4.1.3.5 Ziana Market Growth
Figure 4.2.2.a Psoriasis Market Growth
Figure 4.2.2.b Overall Psoriatic therapeutic market - Growth from 2012 to 2013
Figure 4.2.3.1 Enbrel Market Growth
Figure 4.2.3.2 Humira Market Growth
Figure 4.3.2.1 Atopic Dermatitis Market Growth
Figure 4.3.3.1 Protopic Market Value
Figure 4.3.3.2 Elidel Market Growth
Figure 4.3.3.3 Clobex Market Growth
Figure 4.3.3.4 Elocon Market Growth
Figure 4.4.2.1 Melanoma Skin Cancer Market Growth
Figure 4.4.2.2 Yervoy Market Growth
Figure 4.4.2.3 Zelboraf Market Growth
Figure 4.5.2.1 Skin & Skin Structure Infections Market
Figure 4.5.2.2 Herpes Market
Figure 4.5.3.1 Zyvox Market Growth
Figure 4.5.3.2 Cubicin Market Growth
Figure 4.5.3.3 Zovirax Market Growth
Figure 4.5.3.4 Valtrex Market Growth
Figure 4.5.3.5 Zostavax Market Growth
Figure 4.6.2.a Zostavax Market Growth
Figure 4.6.3.1 Rosacea Market Growth
Figure 4.6.3.2 Oracea Market Growth
Figure 4.7.2.1 Alopecia Market Growth
Figure 4.7.3.1 Propecia Market Growth
Figure 4.7.3.2 Rogaine Market Growth
Figure 6.0.4 Global Market Share for Selected Countries 2013
Figure 6.0.5 Global Market Share for Selected Countries 2018
Figure 6.o.6 Global Market Share for Selected Countries 2023
Figure 6.1.2 The US Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.2.2 The UK Dermatology Market Forecast Figure 2011-2023 ($/bn)
Figure 6.3.2 The French Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.4.2 The German Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.5.2 The Spanish Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.6.2 The Italian Dermatology Market Forecast 2011-2023 ($/bn)
Figure 6.7.2 The Japanese Dermatology Market Forecast 2011-2023 ($/bn)
Table 6.8.2 The ROW Dermatology Market Forecast 2011-2023 ($/bn)
COMPANIES MENTIONED IN THIS REPORT
AAIPharma Services
Abbott
AbbVie Inc
Actavis
Actelion
Aderans Research Institute
Alcon
Allergan, Inc
Almirall, S.A
Amgen
Anacor Pharmaceutical
Anacor Pharmaceuticals
AndroScience Corporation
ApoPharma
Array Biopharma
Ascent Pharmahealth
Aspen Pharmacare
Astellas Pharma
AstraZeneca
AstraZeneca
BASF Pharma
Basilea Pharmaceutica Ltd
Bayer AG
BioForm Medical, Inc
Biofrontera AG
Biofrontera Bioscience GmbH
Biofrontera Pharma GmbH
BioMAS Ltd.
Biotest
Biovail Corporation
Bipharma
BMS
Bristol-Myers Squibb
Can-Fite BioPharma
Celegene Corporation
Cobrek Pharmaceuticals
CollaGenex Pharmaceuticals
Coria Laboratories, Ltd
Cosmo Pharama
Cosmo Pharmaceuticals
Creabilis Therapeutics
Cubist
Cutanea Life sciences
Derma Sciences, Inc
Dermik
Dow Pharmaceutical
DUSA Pharmaceuticals
Eisai Ltd.
Eli Lily
Elorac
EMO-FARM Ltd
Excaliard Pharmaceuticals
Forest Laboratories
Forward-Pharma GmbH
Fougera Pharmaceuticals
Furiex Pharmaceuticals
Galderma
Genzyme
GlaxoSmithKline
Glenmark
Graceway Pharmaceuticals
Helix Biomedix
Heritage Pharmaceuticals
Hill Dermaceuticals, Inc
Hygeia Therapeutics
Hygeia Therapeutics
Immunotech
Impax
Incyte
Intendis
Intendis GmbH
Ipsen
Isotecknika
Italfarmaco
Janssen Biotech
Johnson & Johnson
Kuhnil Pharmaceutical
Laboratoires Roche
Leo Pharma
L'Oréal
Lundbeck
Maruho
Maruho Co. Ltd.
McNeil-PPC
Meda AB
Medarex
MedEfficiency
Medicis
Merck & Co. Inc
Merz Pharma Group
Morria
Mylan
Mylan Inc
Nabriva Therapeutics
Nektar
Nestlé
Novartis, Inc
Obagi
Ortho Dermatologics
Ortho Dermatologics
Paddock
Paddock Laboratories
Paratek Pharmaceuticals
Pelpharma
Perigo
Perrigo
Pfizer
PHA Farmed s.p.
Pharma.MT Ltd
Pharmacenter
Pierre Fabre
PreCision Dermatology
Provectus Pharmaceuticals
Q-Med
Ranbaxy
Rib-X Pharmaceuticals
R-Tech Ueno Ltd
Sandoz
Sanofi
Sanofi Aventis
Schering AG
Schering-Plough
SkinMedica, Inc
Spirig Pharma
Stiefel Laboratories, Inc
Sun Pharmaceutical
Takeda
Targanta Therapeutics
TaroPharma
Tetraphase Pharmaceuticals
The Medicine Company
Theravance
Triax Pharmaceuticals
Trius Therapeutics
Trius Therapeutics, Inc
UCB Inc
University Hospital of Bordeaux
Upjohn
Valeant Pharmaceuticals International, Inc
VBL Therapeutics
Vicept Therapeutics
Warner Chilcott
Watson Pharma Inc
Welichem Biotech
Welichem Biotech Inc.
Wellspring Pharmaceuticals
York Pharma
